These data suggest that merely targeting transporter activity may not be enough to reduce tumor progression, specifically in tumors that exploit HGF/c-Met for tumor cell progression, such as Ras-mutated cancers [43–45], notably, some of the most common mutations in cancer [46]. Here, MET is linked to cancer.